McKesson had previously filed a Class II recall voluntarily last March following the incident, and issued a corrective patch to 10 affected customers. In a statement, McKesson states no patient harm resulted from the incident, and the company is closely monitoring the software.
Class I is the FDA’s highest level of recall, used when there is “a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.” McKesson is currently working with the FDA to close the Class I recall.
More Articles on the FDA:
AHA Seeks FDA Action on Saline, IV Solution Shortage
FDA Approves Implantable Device for Certain Type of Hearing Loss
6 Senators Press for Clarity Over FDA Regulation of Health IT
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.